Skip to main content
. 2021 Dec 23;14(1):69. doi: 10.3390/cancers14010069

Figure 3.

Figure 3

PFS by DM status in patients receiving (a) lanreotide 120 mg and (b) placebo. CI, confidence interval; DM, diabetes mellitus; NR, not reached; PFS, progression-free survival.